Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSun pharma advanced research

    Sun Pharma Advanced Research

    Jump to

    • Bull's Eye: Buy HUL, Biocon, SRF, Godrej Consumer, SPARC, GSFC; Sell Ajanta Pharma

      Ashish Kyal of Waves Strategy Advisors is of the view that one may buy Biocon with a target of Rs 418.

    • Sensex, Nifty rangebound; SPARC, BF Utilities most active

      BF Utilities rallied 8 percent in addition to 14 percent upside in previous session while SPARC climbed over a percent after rising 15 percent on Monday.

    • Bull's Eye: Colgate, Reliance Power, Adani Ent, DLF

      Vishal Jajoo of Nirmal Bang recommends buying Colgate Palmolive with a target price of Rs 1275 and Delta Corp with a target price of Rs 74.50.

    • Bull's Eye: Buy Apollo Tyres, United Phosphorous, UCO Bank

      Sharmila Joshi of Peerless Securities advised buying United Phosphorous with a target price of Rs 142 and Sun Pharma Advanced Research with a target price of Rs 142.

    • Bull's Eye: Buy Karnataka Bank, Adani Ports; short Sintex

      SP Tulsian of sptulsian.com advised buying Karnataka Bank with a target price of Rs 124 and Future Retail with a target price of Rs 106.

    • Stocks in news: M&M, Hind Copper, Tata Coffee, SPARC, MMTC

      KS Oil | Reliance Communications | Kesoram Industries | Infosys | Hindustan Copper | Tata Coffee | MMTC | Apollo Tyres | Jet Airways | Sun Pharma Advanced Research and Wipro are stocks, which are in the news today.

    • Bull's Eye: Buy Bank of Maha, Jet, Kolte-Patil, Tata Global

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • 15 stock ideas for 2013: Nirmal Bang

      Nirmal Bang has come out with its report on stock ideas for 2013.

    • Sun Pharma Adv Q4 net loss of Rs 9 cr

      Sun Pharma Advanced Research has announced its fourth quarter results. The company's Q4 FY11 revenues were up 71% at Rs 58 crore versus Rs 34 crore.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347